Mary L.
Mary L. Alpaugh, Teaneck, NJ US
Patent application number | Description | Published |
---|---|---|
20140242602 | USES OF LABELED HSP90 INHIBITORS - The disclosure provides evidence that the abundance of this particular “oncogenic HSP90” species, which is not dictated by HSP90 expression alone, predicts for sensitivity to HSP90 inhibition therapy, and thus is a biomarker for HSP90 therapy. The disclosure also provides evidence that identifying and measuring the abundance of this oncogenic HSP90 species in tumors predicts of response to HSP90 therapy. “Oncogenic HSP90” is defined herein as the HSP90 fraction that represents a cell stress specific form of chaperone complex, that is expanded and constitutively maintained in the tumor cell context, and that may execute functions necessary to maintain the malignant phenotype. Such roles are not only to regulate the folding of overexpressed (i.e. HER2), mutated (i.e. mB-Raf) or chimeric proteins (i.e. Bcr-Abl), but also to facilitate scaffolding and complex formation of molecules involved in aberrantly activated signaling complexes (i.e. STATS, BCL6). | 08-28-2014 |
20140294725 | USES OF LABELED HSP90 INHIBITORS - The invention concerns various methods of using labeled HSP90 inhibitors to improve treatment of cancer patients with HSP90 inhibitors, including ex vivo and in vivo methods for determining whether a tumor will likely respond to therapy with an HSP90 inhibitor. The disclosure provides a method for determining whether a tumor will likely respond to therapy with an HSP90 inhibitor which comprises the following steps: (a) contacting the tumor or a sample containing cells from the tumor with a detectably labeled HSP90 inhibitor which binds preferentially to a tumor-specific form of HSP90; (b) measuring the amount of labeled HSP90 inhibitor bound to the tumor or the tumor cells in the sample; and (c) comparing the amount of labeled HSP90 inhibitor bound to the tumor or the tumor cells in the sample measured in step (b) to the amount of labeled-HSP90 inhibitor bound to a reference. | 10-02-2014 |
Mary L. Berish, Belle Vernon, PA US
Patent application number | Description | Published |
---|---|---|
20120283679 | Belly binder with a reinforced opening - A belly binder for providing support to an ostomy apparatus is disclosed. The belly binder comprises a flexible band, preferably made of a heavy duty elastic material. The band is wrapped around the abdomen of a wearer for support. Fasteners are attached to the ends of the flexible band to hold the band in position. The flexible band comprises, on its surface, an opening that is adapted to receive an ostomy bag. Further, a support member is attached to the flexible band. The support member is such that it forms a pocket/pouch like structure to hold and support the ostomy bag. | 11-08-2012 |
Mary L. Bouxsein, Brookline, MA US
Patent application number | Description | Published |
---|---|---|
20090087375 | ActRIIB Fusion Polypeptides and Uses Therefor - Methods and compositions for inhibiting growth and differentiation factor-8 (GDF-8) activity in vitro and in vivo are provided. The methods and composition can be used for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or glucose homeostasis. | 04-02-2009 |
20090087433 | ActRIIB Fusion Polypeptides and Uses Therefor - Methods and compositions for inhibiting growth and differentiation factor-8 (GDF-8) activity in vitro and in vivo are provided. The methods and composition can be used for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or glucose homeostasis. | 04-02-2009 |
20110020330 | ANTIBODY INHIBITORS OF GDF-8 AND USES THEREOF - The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), including antibody fragments, which inhibit GDF-8 activity in vitro and in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or insulin metabolism. | 01-27-2011 |
20110250198 | ActRIIB FUSION POLYPEPTIDES AND USES THEREFOR - Methods and compositions for inhibiting growth and differentiation factor-8 (GDF-8) activity in vitro and in vivo are provided. The methods and composition can be used for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or glucose homeostasis. | 10-13-2011 |
20120107928 | Antibody Inhibitors of GDF-8 and Uses Thereof - The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), including antibody fragments, which inhibit GDF-8 activity in vitro and in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or insulin metabolism. | 05-03-2012 |
20150024484 | Antibody Inhibitors of GDF-8 and Uses Thereof - The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), including antibody fragments, which inhibit GDF-8 activity in vitro and in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or insulin metabolism. | 01-22-2015 |
Mary L. Cole, Saint Paul, MN US
Patent application number | Description | Published |
---|---|---|
20140255298 | RADIOPAQUE MARKERS FOR IMPLANTABLE MEDICAL LEADS - A radiopaque marker may include a body formed of a polymer and being adapted to be disposed around a portion of an implantable medical lead and a symbol formed of at least a radiologically dense powder or liquid added to the body and designed to identify the implantable medical lead as being safe application of a medical procedure. In some instances, the symbol may be formed of a polymer mixed with the radiologically dense powder or liquid. The body may also be formed of a polymer mixed with a radiologically dense powder or liquid wherein the mixed polymer forming the symbol is radiologically denser than the mixed polymer forming the body. | 09-11-2014 |
20140257444 | RADIOPAQUE MARKERS FOR IMPLANTABLE MEDICAL LEADS - A radiopaque marker that includes a body being adapted to be disposed around a portion of an implantable medical lead and formed from a polymer mixed with a radiopacifier. The polymer is designed to form a symbol that identifies the implantable medical lead as being designed for safe application of a medical procedure. In some instances, the body of the radiopaque marker includes portions of varying thicknesses, the thick portions of the body being designed to form the symbol that identifies the implantable medical lead as being designed for safe application of a medical procedure such that the thick portions of the body appear more radiologically dense during an imaging procedure. In other instances, the body of the radiopaque marker may have a relatively uniform thickness and is shaped into the symbol that identifies the implantable medical lead as being designed for safe application of a medical procedure. | 09-11-2014 |
Mary L. Disis, Renton, WA US
Patent application number | Description | Published |
---|---|---|
20090215091 | DIAGNOSTIC PANEL OF CANCER ANTIBODIES AND METHODS FOR USE - The invention provides a method for detection of a malignancy in a specimen of bodily fluid. The method comprises contacting the specimen with at least two antigens selected from the group consisting of p53, IGFBP2, Topo2α, cathepsin D, cyclin B, cyclin D1, MUC1, HER-2/neu and CEA. The method further comprises incubating the specimen and the antigen for a duration and under conditions that are sufficient for the formation of immunocomplexes; and detecting the presence or absence of immunocomplex formation between the antigens and antibodies specific for the antigens in the specimen, thereby determining the presence or absence of the malignancy. Also provided is a method for monitoring the effectiveness of cancer therapy related to a malignancy in a warm-blooded animal, a method for distinguishing between Stage I and Stage II colorectal cancer in a specimen of bodily fluid. | 08-27-2009 |
20100010075 | COMPOUNDS FOR ELICITING OR ENHANCING IMMUNE REACTIVITY TO HER-2/neu PROTEIN FOR PREVENTION OR TREATMENT OF MALIGNANCIES IN WHICH THE HER-2/neu ONCOGENE IS ASSOCIATED - Compounds and compositions for eliciting or enhancing immune reactivity to HER-2/neu protein are disclosed. The compounds include polypeptides and nucleic acid molecules encoding such peptides. The compounds may be used for the prevention or treatment of malignancies in which the HER-2/neu oncogene is associated. | 01-14-2010 |
20100087621 | IMMUNE REACTIVITY TO HER-2/NEU PROTEIN FOR DIAGNOSIS AND TREATMENT OF MALIGNANCIES IN WHICH THE HER-2/NEU ONCOGENE IS ASSOCIATED - Methods for the detection, monitoring and treatment of malignancies in which the HER-2/neu oncogene is associated are disclosed. Detection of specific T cell activation (e.g., by measuring the proliferation of T cells) in response to in vitro exposure to the HER-2/neu protein, or detection of immunocomplexes formed between the HER-2/neu protein and antibodies in body fluid, allows the diagnosis of the presence of a malignancy in which the HER-2/neu oncogene is associated. The present invention also discloses methods and compositions, including peptides, for treating such malignancies. | 04-08-2010 |
20100092523 | MOLECULES AND METHODS FOR TREATMENT AND DETECTION OF CANCER - The invention provides a method for inhibiting proliferation of cancer cells, as well as methods for detecting and treating various cancers, including cancer of the ovary, breast, prostate and colon. The method comprises contacting a cancer cell with an IGF-related molecule of the invention or administering an IGF-related vaccine to the cancer patient. In one embodiment, the molecule is an immunogenic peptide derived from IGFBP-2 or from IGF1 R. The invention additionally provides methods for detecting and treating cancer using IGF-related molecules. | 04-15-2010 |
20100310640 | HLA-DR BINDING PEPTIDES AND THEIR USES - The present invention provides HLA-DR (MHC class II) binding peptides derived from the ovarian/breast cancer associated antigens, Human Epidermal Growth Factor Receptor 2 (HER-2/neu), Carcinoembryonic Antigen (CEA), Insulin Growth Factor Binding Protein 2 (IGFBP-2), and Cyclin D1. The immunogenic peptides can be used in cancer vaccines. | 12-09-2010 |
20140377340 | HLA-DR BINDING PEPTIDES AND THEIR USES - The present invention provides HLA-DR (MHC class II) binding peptides derived from the ovarian/breast cancer associated antigens, Human Epidermal Growth Factor Receptor 2 (HER-2/neu), Carcinoembryonic Antigen (CEA), Insulin Growth Factor Binding Protein 2 (IGFBP-2), and Cyclin D1. The immunogenic peptides can be used in cancer vaccines. | 12-25-2014 |
Mary L. Esty, Chevy Chase, MD US
Patent application number | Description | Published |
---|---|---|
20100204750 | METHOD AND APPARATUS FOR UTILIZING AMPLITUDE-MODULATED PULSE-WIDTH MODULATION SIGNALS FOR NEUROSTIMULATION AND TREATMENT OF NEUROLOGICAL DISORDERS USING ELECTRICAL STIMULATION - A computing device-controlled system is described for the generation of amplitude-modulated pulse-width modulation (AMPWM) signals for use in treating neurological dysfunction via cranial neurostimulation, where the AMPWM signal is specifically designed to minimize the electrical impedance of the tissues of the head. A low-frequency carrier signal is determined for the AMPWM signal by measuring EEG activity at a reference site or sites, generally corresponding with the location of suspected brain dysfunction. Carrier signal frequency is variably related to critical frequency components of the EEG power spectral density, determined from statistical analysis of amplitudes and variability, and dynamically changed as a function of time to prevent entrainment. The AMPWM signal is presented to a subject via a plurality of neurostimulation delivery modes for therapeutic use. | 08-12-2010 |
Mary L. Houchin, Rockville, MD US
Patent application number | Description | Published |
---|---|---|
20110212138 | SUSTAINED RELEASE FORMULATIONS USING NON-AQUEOUS CARRIERS - The disclosure provides one-component, injectable, sustained release formulations which comprise microspheres containing active pharmaceutical ingredients (e.g., exenatide), wherein the microspheres are suspended in a non-aqueous carrier. The non-aqueous carrier can be an oil, a fractionated oil, triglycerides, diglycerides, monoglycerides, propylene glycol fatty acid diesters, and the like. The formulations offer distinct advantages of long shelf life for the stability and potency of the formulation and sustained release of active pharmaceutical ingredients to reduce the frequency of medication dosing and to increase patient compliance. | 09-01-2011 |
20150056285 | SUSTAINED RELEASE FORMULATIONS USING NON-AQUEOUS CARRIERS - The disclosure provides one-component, injectable, sustained release formulations which comprise microspheres containing active pharmaceutical ingredients (e.g., exenatide), wherein the microspheres are suspended in a non-aqueous carrier. The non-aqueous carrier can be an oil, a fractionated oil, triglycerides, diglycerides, monoglycerides, propylene glycol fatty acid diesters, and the like. The formulations offer distinct advantages of long shelf life for the stability and potency of the formulation and sustained release of active pharmaceutical ingredients to reduce the frequency of medication dosing and to increase patient compliance. | 02-26-2015 |
Mary L. Kesse, Peoria, IL US
Patent application number | Description | Published |
---|---|---|
20080243354 | Prediction based engine control system and method - A prediction based engine control system is disclosed. The engine control system may have sensor configured to sense a current engine operation and generate a corresponding signal and a controller in communication with the sensor. The controller may be configured to receive the signal, compare the current engine operation to an allowable range of engine operation, predict a future engine operation based on the signal, and limit current engine operation based on the prediction, even when the current engine operation is within the allowable range of operation. | 10-02-2008 |
20080312756 | Virtual sensor system and method - A method is provide for providing sensors for a machine. The method may include obtaining data records including data from a plurality of sensors for the machine and determining a virtual sensor corresponding to one of the plurality of sensors. The method may also include establishing a virtual sensor process model of the virtual sensor indicative of interrelationships between at least one sensing parameters and a plurality of measured parameters based on the data records and obtaining a set of values corresponding to the plurality of measured parameters. Further, the method may include calculating the values of the at least one sensing parameters substantially simultaneously based upon the set of values corresponding to the plurality of measured parameters and the virtual sensor process model and providing the values of the at least one sensing parameters to a control system. | 12-18-2008 |
20100050025 | Virtual sensor network (VSN) based control system and method - A method for providing a virtual sensor network based system. The method may include obtaining project data descriptive of a virtual sensor network to be used in a control system of a machine; establishing a virtual sensor network including a plurality of virtual sensors based on the project data. Each virtual sensor may have a model type, at least one input parameter, and at least one output parameter. The method may also include recording model information, measurement data, and performance information of the virtual sensor network including the plurality of virtual sensors; creating one or more calibration certificates of the virtual sensor network including a plurality of virtual sensors based on the model information, the measurement data, and the performance information; and generating a documentation package associated with the virtual sensor network. The documentation package may include at least an identification, the project data, and at least one calibration certificate of the virtual sensor network including a plurality of virtual sensors. | 02-25-2010 |
Mary L. Kesse, Hanna City, IL US
Patent application number | Description | Published |
---|---|---|
20090288394 | Integrated engine and exhaust after treatment system and method of operating same - An engine system includes an integrated engine and aftertreatment control system via an electronic aftertreatment controller that is in communication with the electronic engine controller. An aftertreatment control algorithm is operable to generate an exhaust control signal and a reductant dosing control signal. The dosing control signal is used to control a flow rate of a reductant (e.g. urea) injection rate into the exhaust system for facilitating a reduction reaction with NOx in the exhaust flow at a suitable downstream catalyst location. The exhaust control signal is communicated to the electronic engine controller, which responds by altering engine operation to change some aspect of the engine exhaust. In one specific example, an ammonia slip event precondition is detected by the electronic aftertreatment controller, and an exhaust control signal in the form of an increase NOx request is communicated to the engine controller, which responds by altering engine operation to increase NOx output in the hopes of preempting the expected ammonia slip event prior to its actual occurrence to maintain undesirable emissions low at the tailpipe. | 11-26-2009 |
20090293457 | System and method for controlling NOx reactant supply - A method is provided for a selective catalytic reduction (SCR) system for reducing a pollutant emission level in exhaust gas of an engine on a machine. The method may include providing a plurality of virtual sensors each having a model type, at least one input parameter, and at least one output parameter. The plurality of virtual sensors may include a first virtual sensor for measuring an emission level of a first component the pollutant and a second virtual sensor for measuring an emission level of a second component the pollutant. The method may also include integrating the plurality of virtual sensors into a virtual sensor network; operating the virtual sensor network to provide the first component emission level and the second component emission level; and calculating a ratio between the first component and the second component based on the first component emission level and the second component emission level. Further, the method may include determining a reactant injection rate of a reactant of the SCR system based on the ratio; and controlling the SCR system to apply the reactant at the reactant injection rate to reduce the pollutant emission level to a desired range. | 12-03-2009 |
Mary L. Schwebel, Minneapolis, MN US
Patent application number | Description | Published |
---|---|---|
20080200885 | Remedy for dry eye syndrome - A treatment for dry eye syndrome. An at least partially sealed chamber including a reservoir for moisture for surrounding the eyes is disclosed. The invention may be transparent for use during the day or in association with prescription or non-prescription lenses. The moisture chamber may also be opaque to act as a blackout mask for sleeping. | 08-21-2008 |
Mary L. Thiesse, Houston, TX US
Patent application number | Description | Published |
---|---|---|
20090209630 | GENE DELIVERY FORMULATIONS AND METHODS FOR TREATMENT OF ISCHEMIC CONDITIONS - The present inventors have developed a novel approach for efficient delivery of angiogenic factors to the cardiac and peripheral vasculature that avoids problems with toxicity inherent to existing delivery technologies. Vectors carrying coding sequences for angiogenic agents including Del-1 or VEGF, or both, can be formulated with poloxamers or other polymers for delivery into ischemic tissue and delivered to areas of peripheral ischemia in a flow to no-flow pattern and to the heart by retrograde venous perfusion. | 08-20-2009 |
Mary L. Thiesse, Burlingame, CA US
Patent application number | Description | Published |
---|---|---|
20110044929 | FORMULATIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISEASES - The present inventors have developed a novel composition and method for inhibiting inflammation and treating of symptoms of tissue ischemia, including that associated with peripheral and cardiac vascular disease by local administration of a pharmaceutical composition including an effective amount of a poloxamer. | 02-24-2011 |